No Data
No Data
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 13 Experts
Ionis Pharmaceuticals Lifts Revenue Forecast After Strong Q1, Oppenheimer Says
Express News | Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $64
Ionis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Ionis Pharmaceuticals Price Target Raised to $50.00/Share From $45.00 by HC Wainwright & Co.
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $51 to $63